Lipocine Submits New Drug Application to FDA for Its Oral Testosterone Replacement Product Candidate, LPCN 1021

By: via Benzinga
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced that it has submitted a 505(b)(2) New Drug ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.